MAHWAH, N.J. / Nov 13, 2025 / Business Wire / KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in three upcoming Investor Conferences.
KORU Medical’s management team is participating at the 16th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 18th, 2025.
KORU Medical’s management team is participating at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 20th, 2025.
KORU Medical's management team is presenting at Piper Sandler’s 37th Annual Healthcare Conference on Tuesday, December 2nd, 2025, at 9:30 am ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com
About KORU Medical Systems
KORU Medical develops, manufactures, and commercializes innovative and patient-centric subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60® and FreedomEDGE® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and High-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
| Last Trade: | US$4.32 |
| Daily Change: | -0.03 -0.69 |
| Daily Volume: | 140,553 |
| Market Cap: | US$199.710M |
November 12, 2025 November 04, 2025 September 18, 2025 August 06, 2025 May 07, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load